-
2024 ESMO BC丨Dato-Dxd’s Good Tolerability Supports Its Role in the Treatment of HR+/HER2- Breast Cancer
At the 2024 ESMO BC conference, new data from the TROPION-Breast01 study highlighted that notable adverse events were typically low-grade, manageable, and did not interfere with patients’ expected treatment.
-
EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation
FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting,…
-
Professor Hongyuan Li : Discussing the Forefront of Subcutaneous Mastectomy and Reconstruction, Building New Peaks of Beauty for Patients | 2024 SFBCS
May 31, 2024Open Immersive ReaderEditor’s Note: From April 19 to April 20, 2024, the 11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS) was grandly held in Chongqing, where domestic and international experts shared vital content on basic breast cancer research, pathology diagnostics, surgical operations, and systemic treatment. In the surgical session, Professor Hongyuan Li from…
-
Professor Hong You: Striving to Link the “Beijing Standard” for Cirrhosis Reversal with Reduced Incidence of Cirrhosis Decompensation and Liver Cancer
Under long-term and repeated stimulation from various causes, a normal liver can develop into cirrhosis. Histologically, cirrhosis is characterized by diffuse liver fibrosis accompanied by collapse of the lobular structure (including microvascular structures) and the formation of pseudolobules, leading to portal hypertension and even liver function decompensation. Professor Hong You’s team at Beijing Friendship Hospital,…
-
Professor Yueqiu Gao: Combining Existing Treatments with Traditional Chinese Medicine Can Improve the Prognosis of Liver Cirrhosis Patients, But Further Research is Needed
According to statistics, there are currently over 400 million people in China suffering from various liver diseases, with approximately one in three people having chronic liver disease. Hepatitis B patients account for about 24% of this number. Liver diseases have become one of the most prevalent threats to people’s health. Chronic liver diseases, such as…
-
EAU24 China’s Voice丨Professor Qiang Wei and Professor Lu Yang’s Team Shine at EAU Conference, Leading Multiple Studies at the International Frontier
The 39th Annual European Association of Urology (EAU) Conference was grandly held from April 5th to 8th, 2024, in Paris, France. As a top-tier event in the global field of urology, the EAU Conference gathered numerous experts and scholars in the urology field to discuss cutting-edge advancements and future trends in urology. At this year’s…
-
BISC 2024 | Professor Qiwen Yang: Progress in China’s Antimicrobial Susceptibility Testing System
Editor’s Note: If antimicrobial drugs are the “express train” to cure, then antimicrobial susceptibility testing information is the “map” for accurate navigation. For a long time, China’s antimicrobial “map” has…
-
Professor Zhang Zhen: Latest Advances in Colorectal Cancer and Highlights of the 2024 CSCO Colorectal Cancer Guidelines Update
Colorectal cancer ranks as the second most prevalent malignancy in China and represents the most common type of gastrointestinal cancer. In recent years, there has been a rapid increase in both incidence and mortality rates. With continuous innovations in relevant diagnostic and therapeutic technologies such as immunotherapy and radiotherapy, the efficacy of treatments for patients…
Connecting Medical Expertise through Media